BR112012002445A2 - uso de um agonista do receptor 4 de melanocortina. - Google Patents

uso de um agonista do receptor 4 de melanocortina.

Info

Publication number
BR112012002445A2
BR112012002445A2 BR112012002445A BR112012002445A BR112012002445A2 BR 112012002445 A2 BR112012002445 A2 BR 112012002445A2 BR 112012002445 A BR112012002445 A BR 112012002445A BR 112012002445 A BR112012002445 A BR 112012002445A BR 112012002445 A2 BR112012002445 A2 BR 112012002445A2
Authority
BR
Brazil
Prior art keywords
agonist
melanocortin receptor
melanocortin
receptor
Prior art date
Application number
BR112012002445A
Other languages
English (en)
Portuguese (pt)
Inventor
Heather A Halem
Michael Dewitt Culler
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of BR112012002445A2 publication Critical patent/BR112012002445A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112012002445A 2009-08-05 2010-07-30 uso de um agonista do receptor 4 de melanocortina. BR112012002445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
BR112012002445A2 true BR112012002445A2 (pt) 2015-10-13

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002445A BR112012002445A2 (pt) 2009-08-05 2010-07-30 uso de um agonista do receptor 4 de melanocortina.

Country Status (12)

Country Link
US (2) US20120135923A1 (https=)
EP (1) EP2461681A4 (https=)
JP (1) JP2013501053A (https=)
KR (1) KR20120059520A (https=)
CN (1) CN102548399A (https=)
AU (1) AU2010279719A1 (https=)
BR (1) BR112012002445A2 (https=)
CA (1) CA2769883A1 (https=)
IN (1) IN2012DN01493A (https=)
MX (1) MX2012001513A (https=)
RU (1) RU2012108110A (https=)
WO (1) WO2011017209A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2833676C (en) * 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
CA2862444A1 (en) * 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
WO2019219714A1 (en) * 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
JP2008519008A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
PL2286825T3 (pl) * 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
ES2618315T3 (es) * 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
NZ585131A (en) * 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity

Also Published As

Publication number Publication date
WO2011017209A1 (en) 2011-02-10
CA2769883A1 (en) 2011-02-10
JP2013501053A (ja) 2013-01-10
MX2012001513A (es) 2012-05-22
CN102548399A (zh) 2012-07-04
AU2010279719A1 (en) 2012-03-01
US20120135923A1 (en) 2012-05-31
EP2461681A4 (en) 2013-04-24
KR20120059520A (ko) 2012-06-08
RU2012108110A (ru) 2013-09-10
IN2012DN01493A (https=) 2015-06-05
US20130331324A1 (en) 2013-12-12
EP2461681A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
EP2350060A4 (en) Melanocortin receptor AGONISTS
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
BR112012000107A2 (pt) receptores de células t.
BRPI0820508A2 (pt) antagonistas de lna cujo alvo é o receptor de andrógeno
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BRPI0821668A2 (pt) Uso
BRPI0806500A2 (pt) Agonistas gpcr de piperidina
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP2041120A4 (en) MELANOCORTIN RECEPTOR AGONISTS
BRPI1007017A2 (pt) uso de um composto.
BRPI0915134A2 (pt) composto, e, uso de um composto
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
BRPI0810926A2 (pt) Antagonista de crig
BR112012002445A2 (pt) uso de um agonista do receptor 4 de melanocortina.
BRPI0812991A2 (pt) Utilização de combustível melhorado
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BRPI1015091A2 (pt) novo uso
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
BRPI1011036A2 (pt) uso
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.